As a tumour suppressor, miR-141-3p inhibits cell proliferation, migration, and invasion in non-small-cell lung cancer [127], in chronic myeloid leukaemia by targeting RAB32 [128], and in triple-negative breast cancer by suppressing the Wnt/β–catenin signalling pathway [129]. This evidence concerns the gene RAB32 and chronic myelogenous leukemia, BCR-ABL1 positive.